TIBET PHARMA(SH:600211) Shang Hai Zheng Quan Bao·2025-09-16 20:19Group 1 - The company has provided guarantees for its subsidiary, Xizang Nuodikan Biopharmaceutical Co., Ltd., to secure bank credit facilities totaling up to RMB 80 million from Shanghai Pudong Development Bank and Industrial Bank [1][4][5] - The board of directors and the annual shareholders' meeting approved the proposal for a total credit limit of up to RMB 1 billion for the company and its subsidiaries in 2025, with the subsidiary's limit set at RMB 800 million [2][6] - The guarantees are within the approved limits and do not require additional approval, aligning with relevant regulations [2][6] Group 2 - The guarantees provided cover not only the principal debt but also interest, penalties, and other related costs, ensuring comprehensive coverage for the creditors [4][5] - The company maintains a total external guarantee amount of RMB 800 million, which represents 20.24% of its latest audited net assets, with no overdue guarantees reported [6] - The subsidiary's good credit status and debt repayment ability justify the guarantees, enhancing financial flexibility and operational efficiency for long-term development [5][6]